vs
Side-by-side financial comparison of GLACIER BANCORP, INC. (GBCI) and Bio-Techne (TECH). Click either name above to swap in a different company.
Bio-Techne is the larger business by last-quarter revenue ($311.4M vs $306.8M, roughly 1.0× GLACIER BANCORP, INC.). GLACIER BANCORP, INC. runs the higher net margin — 26.8% vs 16.4%, a 10.4% gap on every dollar of revenue. Over the past eight quarters, GLACIER BANCORP, INC.'s revenue compounded faster (24.3% CAGR vs 1.3%).
Glacier Bancorp, Inc. is a regional multi-bank holding company headquartered in Kalispell, Montana, United States. It is a successor corporation to the Delaware corporation originally incorporated in 1990. The company provides personal and commercial banking services from 221 locations in Montana, Idaho, Utah, Washington, Wyoming, Colorado, Arizona, and, Nevada.
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
GBCI vs TECH — Head-to-Head
Income Statement — Q1 FY2026 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $306.8M | $311.4M |
| Net Profit | $82.1M | $51.0M |
| Gross Margin | — | 66.9% |
| Operating Margin | — | 24.2% |
| Net Margin | 26.8% | 16.4% |
| Revenue YoY | — | -1.5% |
| Net Profit YoY | — | 126.0% |
| EPS (diluted) | $0.63 | $0.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $306.8M | $311.4M | ||
| Q4 25 | $306.5M | $295.9M | ||
| Q3 25 | $260.7M | — | ||
| Q2 25 | $240.6M | $317.0M | ||
| Q1 25 | $222.6M | $316.2M | ||
| Q4 24 | $223.0M | $297.0M | ||
| Q3 24 | $214.9M | $289.5M | ||
| Q2 24 | $198.7M | $306.1M |
| Q1 26 | $82.1M | $51.0M | ||
| Q4 25 | $63.8M | $38.0M | ||
| Q3 25 | $67.9M | — | ||
| Q2 25 | $52.8M | $-17.7M | ||
| Q1 25 | $54.6M | $22.6M | ||
| Q4 24 | $61.8M | $34.9M | ||
| Q3 24 | $51.1M | $33.6M | ||
| Q2 24 | $44.7M | $40.6M |
| Q1 26 | — | 66.9% | ||
| Q4 25 | — | 64.6% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 62.7% | ||
| Q1 25 | — | 67.9% | ||
| Q4 24 | — | 65.3% | ||
| Q3 24 | — | 63.2% | ||
| Q2 24 | — | 66.4% |
| Q1 26 | — | 24.2% | ||
| Q4 25 | 24.9% | 18.4% | ||
| Q3 25 | 32.7% | — | ||
| Q2 25 | 27.1% | -7.5% | ||
| Q1 25 | 28.5% | 12.2% | ||
| Q4 24 | 33.0% | 16.0% | ||
| Q3 24 | 28.9% | 13.8% | ||
| Q2 24 | 27.3% | 15.0% |
| Q1 26 | 26.8% | 16.4% | ||
| Q4 25 | 20.8% | 12.8% | ||
| Q3 25 | 26.0% | — | ||
| Q2 25 | 21.9% | -5.6% | ||
| Q1 25 | 24.5% | 7.1% | ||
| Q4 24 | 27.7% | 11.7% | ||
| Q3 24 | 23.8% | 11.6% | ||
| Q2 24 | 22.5% | 13.3% |
| Q1 26 | $0.63 | $0.32 | ||
| Q4 25 | $0.49 | $0.24 | ||
| Q3 25 | $0.57 | — | ||
| Q2 25 | $0.45 | $-0.11 | ||
| Q1 25 | $0.48 | $0.14 | ||
| Q4 24 | $0.55 | $0.22 | ||
| Q3 24 | $0.45 | $0.21 | ||
| Q2 24 | $0.39 | $0.26 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.4B | $209.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $4.2B | $2.1B |
| Total Assets | $31.7B | $2.6B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $1.4B | $209.8M | ||
| Q4 25 | — | $172.9M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $162.2M | ||
| Q1 25 | — | $140.7M | ||
| Q4 24 | — | $177.5M | ||
| Q3 24 | — | $187.5M | ||
| Q2 24 | — | $152.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | $260.0M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $346.0M | ||
| Q1 25 | — | $330.0M | ||
| Q4 24 | — | $300.0M | ||
| Q3 24 | — | $300.0M | ||
| Q2 24 | — | $319.0M |
| Q1 26 | $4.2B | $2.1B | ||
| Q4 25 | $4.2B | $2.0B | ||
| Q3 25 | $3.6B | — | ||
| Q2 25 | $3.5B | $1.9B | ||
| Q1 25 | $3.3B | $2.0B | ||
| Q4 24 | $3.2B | $2.1B | ||
| Q3 24 | $3.2B | $2.1B | ||
| Q2 24 | $3.1B | $2.1B |
| Q1 26 | $31.7B | $2.6B | ||
| Q4 25 | $32.0B | $2.5B | ||
| Q3 25 | $29.0B | — | ||
| Q2 25 | $29.0B | $2.6B | ||
| Q1 25 | $27.9B | $2.6B | ||
| Q4 24 | $27.9B | $2.7B | ||
| Q3 24 | $28.2B | $2.7B | ||
| Q2 24 | $27.8B | $2.7B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.13× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.18× | ||
| Q1 25 | — | 0.16× | ||
| Q4 24 | — | 0.14× | ||
| Q3 24 | — | 0.14× | ||
| Q2 24 | — | 0.15× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GBCI
| Net Interest Income | $268.7M | 88% |
| Noninterest Income | $38.1M | 12% |
TECH
| Protein Sciences segment revenue | $226.2M | 73% |
| Diagnostics and Spatial Biology segment revenue | $85.6M | 27% |
| Other revenue (1) | $5.4M | 2% |
